AI assistant
aTYR PHARMA INC — Director's Dealing 2021
May 20, 2021
34337_dirs_2021-05-20_883e5acc-7744-4ec2-92ea-e63ca1b0b6d7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2021-05-18
Reporting Person: SCHIMMEL PAUL (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-18 | Common Stock | P | 50000 | $3.98 | Acquired | 113023 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2890 | Direct |
| Common Stock | 429143 | Indirect |
Footnotes
F1: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.
F2: Represents weighted average price for the shares. The shares were purchased at prices ranging from $3.95 to $4.00 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.